- Merck KGaA of Germany says the "Green Shoe" option of underwriting banks to cover multiple allotments made available via authorized capital when the company went public (Marketletters passim) has now been exercised to its full value of 5 million ordinary shares. At the same time, Merck used its rights to increase the complementary capital by a nominal 35 million Deutschemarks to 635 million marks ($450.5 million). And it divested its diagnostic business' fully-automated electrophoresis systems to Olympus Diagnostica GmbH.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze